{'fraction_non_alphanumeric': 0.026360067302299495, 'fraction_numerical': 0.007851934941110488, 'mean_word_length': 5.194444444444445, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Posterior segment involvement in HIV-related eye disease after commencement of highly-active antiretroviral therapy (HAART)].

The panel of therapeutic options available for the treatment of retroviral disorders has expanded explosively in recent years with the result that it has now become possible to reconstitute the immune function of individuals with advanced HIV-disease to a remarkable degree. The ophthalmologist is thus confronted with completely new clinical situations, courses of treatment and decisions. For example, a CMV-retinitis developing within six weeks of the onset of HAART does not necessarily require specific treatment, and reactivation of a retinitis within the same time span is often barely distinguishable from an inflammatory reaction induced by the reconstituted lymphocytes. Marked cellular infiltration of the vitreous--in the absence of an active retinal or chorioretinal lesion--is the hallmark of this immune-recovery vitreitis and responds nicely to systemic steroid treatment. In the course of retinitis, macular edema and epiretinal membrane formation are not uncommonly responsible for visual impairment. If, on the other hand, immunological parameters remain stable during the course of three months, i.e., if the CD4 cell count is more than 150-250 microliters and the plasma load of HIV-1 is less than 5-10,000 copies/microliter, then what has until now been deemed to be a lifelong therapy for CMV-retinitis may be interrupted, provided the clinical (i.e., retinal) situation can be controlled on a regular basis. In this article, an attempt is made to discuss and interpret clinical findings pertaining to posterior segment involvement in ocular HIV disease, with a view to guiding the clinical practitioner in his/her course of action.